Rosacea: The blessing of the celts – An approach to pathogenesis through translational research

Acta Dermato-Venereologica

Volumn 96, Issue 2, 2016, Pages 147-156

  Melnik, Bodo C ^a  

^a UNIVERSITY OF OSNABRÜCK   (Germany)

Author keywords

C; CAMP; Cathelicidin; Celts; EBP ; ER stress; HLA DRA; LL 37; Multiple sclerosis; Osteopontin; Rosacea; Sphingosine 1 phosphate; Vitamin D

Indexed keywords

AVERMECTIN; AZELAIC ACID; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CCAAT ENHANCER BINDING PROTEIN ALPHA; DOXYCYCLINE; ESTROGEN; HLA DR ANTIGEN; ISOTRETINOIN; IVERMECTIN; METRONIDAZOLE; MINOCYCLINE; OSTEOPONTIN; SPHINGOSINE 1 PHOSPHATE; TETRACYCLINE DERIVATIVE; VITAMIN D; VITAMIN D RECEPTOR; AUTACOID; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ANGIOGENESIS; ARTICLE; BACTERICIDAL ACTIVITY; DISEASE EXACERBATION; DNA POLYMORPHISM; ENDOPLASMIC RETICULUM STRESS; FIBROSIS; FLUSHING; FOOD INTAKE; GENE EXPRESSION; GRANULOMA; HEAT; HOST RESISTANCE; HUMAN; INFLAMMATION; LUPUS VULGARIS; MULTIPLE SCLEROSIS; MYCOBACTERIUM; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RED WINE; ROSACEA; SEBACEOUS GLAND; SEBACEOUS GLAND DISEASE; SKIN ALLERGY; ULTRAVIOLET RADIATION; UPREGULATION; WINTER; ANALOGS AND DERIVATIVES; ANIMAL; CAUCASIAN; EPIDEMIOLOGY; ETHNOLOGY; GENETICS; GENOTYPE; METABOLISM; MOLECULAR EVOLUTION; MUTATION; PHENOTYPE; RISK FACTOR; SCANDINAVIA; SIGNAL TRANSDUCTION; SKIN; TRANSLATIONAL RESEARCH;

ANIMALS; CATHELICIDINS; ENDOPLASMIC RETICULUM STRESS; EUROPEAN CONTINENTAL ANCESTRY GROUP; EVOLUTION, MOLECULAR; GENOTYPE; HUMANS; INFLAMMATION MEDIATORS; LYSOPHOSPHOLIPIDS; MUTATION; PHENOTYPE; PROMOTER REGIONS, GENETIC; RISK FACTORS; ROSACEA; SCANDINAVIAN AND NORDIC COUNTRIES; SIGNAL TRANSDUCTION; SKIN; SPHINGOSINE; TRANSLATIONAL MEDICAL RESEARCH; VITAMIN D;

EID: 84954535020     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-2220     Document Type: Article

References (199)

1. DelRosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis 2006; 78: 997-100.
2. Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007; 13: 975-980.
3. Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci 2009; 55: 77-81.
4. Gerber PA, Buhren BA, Steinhoff M, Homey B. Rosacea: the cytokine and chemokine network. J Investig Dermatol Symp Proc 2011; 15: 40-47.
5. Meyer-Hoffert U, Schröder JM. Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatol Symp Proc 2011; 15: 16-23.
6. Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc 2011; 15: 12-15.
7. Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol 2012; 24: 126-135.
8. Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol 2013; 69: S15-26.
9. Yamasaki K, Schauber J, Coda A, Lin H, Dorschner RA, Schechter NM, et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicins in skin. FASEB J 2006; 20: 2068-2080.
10. Yamasaki K, Kanada K, Macleod DT, Borkowski AW, Morizane S, Nakatsuji T, et al. TLR2 expression is increased in rosacea and stimulated enhanced serine protease production by keratinocytes. J Invest Dermatol 2011; 131: 688-697.
11. Kai-Larsen Y, Agerberth B. The role of the multifunctional peptide LL-37 in host defense. Front Biosci 2008; 13: 3760-3767.
12. Braff MH, Bardan A, Nizet V, Gallo RL. Cutaneous defense mechanisms by antimicrobial peptides. J Invest Dermatol 2005; 125: 9-13.
13. Lee DY, Yamasaki K, Rudsil J, Zouboulis CC, Park GT, Yang JM, et al. Sebocytes express functional cathelicidin antimicrobial peptides and can act to kill propionibacterium acnes. J Invest Dermatol 2008; 128: 1863-1866.
14. Quarterman MJ, Johnson DW, Abele DC, Lesher JL Jr, Hull DS, Davis LS. Ocular rosacea. Signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol 1997; 133: 49-54.
15. Henzler Wildman KA, Lee DK, Ramamoorthy A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry 2003; 42: 6545-6558.
16. Wang G, Mishra B, Lau K, Lushnikova T, Golla R, Wang X. Antimicrobial peptides in 2014. Pharmaceuticals (Basel) 2015; 8: 123-150.
17. Méndez-Samperio P. The human cathelicidin hCAP18/LL- 37: a multifunctional peptide involved in mycobacterial infections. Peptides 2010; 31: 1791-1798.
18. Selvaraj P. Vitamin D, vitamin D receptor, and cathelicidin in the treatment of tuberculosis. Vitam Horm 2011; 86: 307-325.
19. Liu PT, Krutzik SR, Modlin RL. Therapeutic implications of the TLR and VDR partnership. Trends Mol Med 2007; 13: 117-124.
20. Fahy RJ, Wewers MD. Pulmonary defense and the human cathelicidin hCAP-18/LL-37. Immunol Res 2005; 31: 75-89.
21. Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001; 414: 454-457.
22. Roby KD, Nardo AD. Innate immunity and the role of the antimicrobial peptide cathelicidin in inflammatory skin disease. Drug Discov Today Dis Mech 2013; 10: e79-e82.
23. Howell MD, Wollenberg A, Gallo RL, Flaig M, Streib JE, Wong C, et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 2006; 117: 836-841.
24. Travis SM, Anderson NN, Forsyth WR, Espiritu C, Conway BD, Greenberg EP, et al. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun 2000; 68: 2748-2755.
25. Tsai PW, Yang CY, Chang HT, Lan CY. Human antimicrobial peptide LL-37 inhibits adhesion of Candida albicans by interacting with yeast cell-wall carbohydrates. PLoS One 2011; 6: e17755.
26. Barbeiro DF, Barbeiro HV, Zampieri FG, César Machado MC, Torggler Filho F, Gomes Cunha DM, et al. Cathelicidin LL-37 bloodstream surveillance is down regulated during septic shock. Microbes Infect 2013; 15: 342-346.
27. Karlsson J, Carlsson G, Ramme KG, Hägglund H, Fadeel B, Nordenskjöld M, et al. Low plasma levels of the protein pro-LL-37 as an early indication of severe disease in patients with chronic neutropenia. Br J Haematol 2007; 137: 166-169.
28. Pütsep K, Carlsson G, Boman HG, Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 2002; 360: 1144-1149.
29. Gombart AF, Bhan I, Borregaard N, Tamez H, Camargo CA Jr, Koeffler HP, et al. Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis 2009; 48: 418-424.
30. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sørensen O, Borregaard N, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 2003; 120: 379-389.
31. Huang LC, Petkova TD, Reins RY, Proske RJ, McDermott AM. Multifunctional roles of human cathelicidin (LL-37) at the ocular surface. Invest Ophthalmol Vis Sci 2006; 47: 2369-2380.
32. Wu WK, Wang G, Coffelt SB, Betancourt AM, Lee CW, Fan D, et al. Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications. Int J Cancer 2010; 127: 1741-1747.
33. Hase K, Murakami M, Iimura M, Cole SP, Horibe Y, Ohtake T, et al. Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against Helicobacter pylori. Gastroenterology 2003; 125: 1613-1625.
34. Rahman S, Rehn A, Rahman J, Andersson J, Svensson M, Brighenti S. Pulmonary tuberculosis patients with a vitamin D deficiency demonstrate low local expression of the antimicrobial peptide LL-37 but enhanced FoxP3(+) regulatory T cells and IgG-secreting cells. Clin Immunol 2015; 156: 85-97.
35. Dixon BM, Barker T, McKinnon T, Cuomo J, Frei B, Borregaard N, et al. Positive correlation between circulating cathelicidin antimicrobial peptide (hCAP18/LL-37) and 25-hydroxyvitamin D levels in healthy adults. BMC Res Notes 2012; 5: 575.
36. Glass D, Lens M, Swaminathan R, Spector TD, Bataille V. Pigmentation and vitamin D metabolism in Caucasians: low vitamin D serum levels in fair skin types in the UK. PLoS One 2009; 4: e6477.
37. Park K, Elias PM, Oda Y, Mackenzie D, Mauro T, Holleran WM, et al. Regulation of cathelicidin antimicrobial peptide expression by an endoplasmic reticulum (ER) stress signaling, vitamin D receptor-independent pathway. J Biol Chem 2011; 286: 34121-34130.
38. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173: 2909-2912.
39. Zhang K, Kaufman RJ. From endoplasmic-reticulum stress to the inflammatory response. Nature 2008; 454: 455-462.
40. Melnik BC. Endoplasmic reticulum stress: key promoter of rosacea pathogenesis. Exp Dermatol 2014; 23: 868-873.
41. Chen W, Yang CC, Sheu HM; Seltmann H, Zouboulis CC. Expression of peroxisome proliferator-activated receptor and CCAAT/enhancer binding protein transcription factors in cultured human sebocytes. J Invest Dermatol 2003; 121: 441-447.
42. Jiang HY, Wek SA, McGrath BC, Scheuner D, Kaufman RJ, Cavener DR, et al. Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses. Mol Cell Biol 2003; 23: 5651-5663.
43. Deng J, Lu PD, Zhang Y, Scheuner D, Kaufman RJ, Sonenberg N, et al. Translational repression mediates activation of nuclear factor kappa B by phosphorylated translation initiation factor 2. Mol Cell Biol 2004; 24: 10161-10168.
44. Shimasaki S, Koga T, Shuto T, Suico MA, Sato T, Watanabe K, et al. Endoplasmic reticulum stress increases the expression and function of toll-like receptor-2 in epithelial cells. Biochem Biophys Res Commun 2010; 402: 235-240.
45. Lee SY, Hong IK, Kim BR, Shim SM, Lee JS, Lee HY, et al. Activation of sphingosine kinase 2 by endoplasmic reticulum stress ameliorates hepatic steatosis and insulin resistance. Hepatology 2015; 62: 135-146.
46. Hagen N, Van Veldhoven PP, Proia RL, Park H, Merrill AH Jr, van Echten-Deckert G. Subcellular origin of sphingosine 1-phosphate is essential for its toxic effect in lyasedeficient neurons. J Biol Chem 2009; 284: 11346-11353.
47. Naetzker S, Hagen N, Echten-Deckert G. Activation of p38 mitogen-activated protein kinase and partial reactivation of the cell cycle by cis-4-methylsphingosine direct postmitotic neurons towards apoptosis. Genes Cells 2006; 11: 269-279.
48. Park K, Elias PM, Shin KO, Lee YM, Hupe M, Borkowski AW, et al. A novel role of a lipid species, sphingosine- 1-phosphate, in epithelial innate immunity. Mol Cell Biol 2013; 33: 752-762.
49. Park K, Lee S, Lee YM. Sphingolipids and antimicrobial peptides: function and roles in atopic dermatitis. Biomol Ther (Seoul) 2013; 21: 251-257.
50. Yu J, Mookherjee N, Wee K, Bowdish DM, Pistolic J, Li Y, et al. Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways. J Immunol 2007; 179: 7684-7691.
51. Kasimsetty SG, DeWolf SE, Shigeoka AA, McKay DB. Regulation of TLR2 and NLRP3 in primary murine renal tubular epithelial cells. Nephron Clin Pract 2014; 127: 119-123.
52. Segovia J, Sabbah A, Mgbemena V, Tsai SY, Chang TH, Berton MT, et al. TLR2/MyD88/NF-κB pathway, reactive oxygen species, potassium efflux activates NLRP3/ASC inflammasome during respiratory syncytial virus infection. PLoS One 2012; 7: e29695.
53. Kelhälä HL, Palatsi R, Fyhrquist N, Lehtimäki S, Väyrynen JP, Kallioinen M, et al. IL-17/Th17 pathway is activated in acne lesions. PLoS One 2014; 9: e105238.
54. Wladis EJ, Iglesias BV, Adam AP, Gosselin EJ. Molecular biologic assessment of cutaneous specimens of ocular rosacea. Ophthal Plast Reconstr Surg 2012; 28: 246-250.
55. Kahlenberg JM, Carmona-Rivera C, Smith CK, Kaplan MJ. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol 2013; 190: 1217-1226.
56. Sirisinha S. Insight into the mechanisms regulating immune homeostasis in health and disease. Asian Pac J Allergy Immunol 2011; 29: 1-14.
57. Lee HM, Yuk JM, Kim KH, Jang J, Kang G, Park JB, et al. Mycobacterium abscessus activates the NLRP3 inflammasome via Dectin-1-Syk and p62/SQSTM1. Immunol Cell Biol 2012; 90: 601-610.
58. Li N, Yamasaki K, Saito R, Fukushi-Takahashi S, Shimada-Omori R, Asano M, et al. Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36γ induction in human epidermal keratinocytes. J Immunol 2014; 193: 5140-5148.
59. Peric M, Koglin S, Kim SM, Morizane S, Besch R, Prinz JC, et al. IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. J Immunol 2008; 181: 8504-8512.
60. Chen X, Takai T, Xie Y, Niyonsaba F, Okumura K, Ogawa H. Human antimicrobial peptide LL-37 modulates proinflammatory responses induced by cytokine milieus and double-stranded RNA in human keratinocytes. Biochem Biophys Res Commun 2013; 433: 532-537.
61. Muto Y, Wang Z, Vanderberghe M, Two A, Gallo RL, Di Nardo A. Mast cells are key mediators of cathelicidininitiated skin inflammation in rosacea. J Invest Dermatol 2014; 134: 2728-2736.
62. Fujimoto N, Mitsuru M, Tanaka T. Successful treatment of Morbihan disease with long-term minocycline and its association with mast cell infiltration. Acta Derm Venereol 2015; 95: 368-369.
63. Niyonsaba F, Hirata M, Ogawa H, Nagaoka I. Epithelial cell-derived antibacterialpeptides human beta-defensins and cathelicidin: multifunctional activities on mast cells. Curr Drug Targets Inflamm Allergy 2003; 2: 224-231.
64. Olivera A, Rivera J. An emerging role for the lipid mediator sphingosine-1-phosphate in mast cell effector function and allergic disease. Adv Exp Med Biol 2011; 716: 123-142.
65. Olivera A, Kitamura Y, Wright LD, Allende ML, Chen W, Kaneko-Goto T, et al. Sphingosine-1-phosphate can promote mast cell hyper-reactivity through regulation of contactin- 4 expression. J Leukoc Biol 2013; 94: 1013-1024.
66. Hamidi S, Schäfer-Korting M, Weindl G. TLR2/1 and sphingosine 1-phosphate modulate inflammation, myofibroblast differentiation and cell migration in fibroblasts. Biochim Biophys Acta 2014; 1841: 484-494.
67. Okun E, Griffioen KJ, Mattson MP. Toll-like receptor signaling in neuronal plasticity and disease. Trends Neurosci 2011; 34: 269-281.
68. Liu T, Gao YJ, Ji RR. Emerging role of toll-like receptors in the control of pain and itch. Neurosci Bull 2012; 28: 131-144.
69. Kim D, Kim MA, Cho IH, Kim MS, Lee S, Jo EK, et al. A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity. J Biol Chem 2007; 282: 14975-14983.
70. Guerrero AT, Cunha TM, Verri WA Jr, Gazzinelli RT, Teixeira MM, Cunha FQ, et al. Toll-like receptor 2/MyD88 signaling mediates zymosan-induced joint hypernociception in mice: participation of TNF-α, IL-1β and CXCL1/ KC. Eur J Pharmacol 2012; 674: 51-57.
71. Lonne-Rahm S B, Fischer T, Berg M. Stinging and rosacea. Acta Derm Venereol 1999; 79: 460-461.
72. Guzman-Sanchez D A, Ishiuji Y, Patel T, Fountain J, Chan YH, Yosipovitch G. Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea. J Am Acad Dermatol 2007; 57: 800-805.
73. Herzinger T, Kleuser B, Schäfer-Korting M, Korting HC Sphingosine-1-phosphate signaling and the skin. Am J Clin Dermatol 2007; 8: 329-336.
74. Camprubí-Robles M, Mair N, Andratsch M, Benetti C, Beroukas D, Rukwied R, et al. Sphingosine-1-phosphateinduced nociceptor excitation and ongoing pain behavior in mice and humans is largely mediated by S1P3 receptor. J Neurosci 2013; 33: 2582-2592.
75. Zhang YH, Fehrenbacher JC, Vasko MR, Nicol GD. Sphingosine-1-phosphate via activation of a G-proteincoupled receptor(s) enhances the excitability of rat sensory neurons. J Neurophysiol 2006; 96: 1042-1052.
76. Wilkin JK. Effect of subdepressor clonidine on flushing reactions in rosacea. Change in malar thermal circulation index during provoked flushing reactions. Arch Dermatol 1983; 119: 211-214.
77. Zhou J, An H, Xu H, Liu S, Cao X. Heat shock up-regulates expression of Toll-like receptor-2 and Toll-like receptor-4 in human monocytes via p38 kinase signal pathway. Immunology 2005; 114: 522-530.
78. Mair N, Benetti C, Andratsch M, Leitner MG, Constantin CE, Camprubí-Robles M, et al. Genetic evidence for involvement of neuronally expressed S1P1 receptor in nociceptor sensitization and inflammatory pain. PLoS One 2011; 6: e17268.
79. Sulk M, Seeliger S, Aubert J, Schwab VD, Cevikbas F, Rivier M, et al. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J Invest Dermatol 2012; 132: 1253-1262.
80. Langeslag M, Quarta S, Leitner MG, Kress M, Mair N. Sphingosine 1-phosphate to p38 signaling via S1P1 receptor and Gαi/o evokes augmentation of capsaicin-induced ionic currents in mouse sensory neurons. Mol Pain 2014; 10: 74.
81. Salzer S, Kresse S, Hirai Y, Koglin S, Reinholz M, Ruzicka T, et al. Cathelicidin peptide LL-37 increases UVBtriggered inflammasome activation: possible implications for rosacea. J Dermatol Sci 2014; 76: 173-179.
82. Anand S, Chakrabarti E, Kawamura H, Taylor CR, Maytin EV. Ultraviolet light (UVB and UVA) induces the damageresponsive transcription factor CHOP/gadd153 in murine and human epidermis: evidence for a mechanism specific to intact skin. J Invest Dermatol 2005; 125: 323-333.
83. Mera K, Kawahara K, Tada K, Kawai K, Hashiguchi T, Maruyama I, et al. ER signaling is activated to protect human HaCaT keratinocytes from ER stress induced by environmental doses of UVB. Biochem Biophys Res Commun 2010; 397: 350-354.
84. Park YK, Jang BC. UVB-induced anti-survival and proapoptotic effects on HaCaT human keratinocytes via caspase- and PKC-dependent downregulation of PKB, HIAP-1, Mcl-1, XIAP and ER stress. Int J Mol Med 2014; 33: 695-702.
85. Wu S, Tan M, Hu Y, Wang JL, Scheuner D, Kaufman RJ. Ultraviolet light activates NFkappaB through translational inhibition of IkappaBalpha synthesis. J Biol Chem 2004; 279: 34898-34902.
86. Felton S, Navid F, Schwarz A, Schwarz T, Gläser R, Rhodes LE. Ultraviolet radiation-induced upregulation of antimicrobial proteins in health and diseases. Photochem Photobiol Sci 2013; 12: 29-36.
87. Komori R, Taniguchi M, Ichikawa Y, Uemura A, Oku M, Wakabayashi S, et al. Ultraviolet A induces endoplasmic reticulum stress response in human dermal fibroblasts. Cell Struct Funct 2012; 37: 49-53.
88. Uchida Y, Houben E, Park K, Douangpanya S, Lee YM, Wu BX, et al. Hydrolytic pathway protects against ceramide-induced apoptosis in keratinocytes exposed to UVB. J Invest Dermatol 2010; 130: 2472-2480.
89. Rath E, Haller D. Inflammation and cellular stress: a mechanistic link between immune-mediated and metabolically driven pathologies. Eur J Nutr 2011; 50: 219-233.
90. Park K, Elias PM, Hupe M, Borkowski AW, Gallo RL, Shin KO et al. Resveratrol stimulates sphingosine- 1-phosphate signaling of cathelicidin production. J Invest Dermatol 2013; 133: 1942-1949.
91. Park K, Kim YI, Shin KO, Seo HS, Kim JY, Mann T, et al. The dietary ingredient, genistein, stimulates cathelicidin antimicrobial peptide expression through a novel S1P-dependent mechanism. J Nutr Biochem 2014; 25: 734-740.
92. Ferahbas A, Utas S, Mistik S, Uksal U, Peker D. Rosacea fulminans in pregnancy: case report and review of the literature. Am J Clin Dermatol 2006; 7: 141-144.
93. Schmidt JB, Raff M, Spona J. Do sexual steroids contribute to the pathomechanism of rosacea? A study of estrogen and androgen receptors in acne rosacea. Acta Derm Venereol 1983; 63: 64-66.
94. Lüthje P, Brauner H, Ramos NL, Ovregaard A, Gläser R, Hirschberg AL, et al. Estrogen supports urothelial defense mechanisms. Sci Transl Med 2013; 5: 190ra80.
95. Piwnica D, Rosignoli C, de Ménonville ST, Alvarez T, Schuppli Nollet M, Roye O, et al. Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine. J Dermatol Sci 2014; 75: 49-54.
96. Tong LX, Moore AY. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea. Expert Rev Clin Pharmacol 2014; 7: 567-577.
97. Igarashi J, Michel T. Sphingosine-1-phosphate and modulation of vascular tone. Cardiovasc Res 2009; 82: 212-220.
98. Levkau B. Sphingosine-1-phosphate in the regulation of vascular tone: a finely tuned integration system of S1P sources, receptors, and vascular responsiveness. Circ Res 2008; 103: 231-233.
99. Helfrich YR, Maier LE, Cui Y, Fisher GJ, Chubb H, Fligiel S, et al. Clinical, histologic, and molecular analysis of differences between erythematotelangiectatic rosacea and telangiectatic photoaging. JAMA Dermatol 2015; 151: 825-836.
100. Aroni K, Tsagroni E, Kavantzas N, Patsouris E, Ioannidis E. A study of the pathogenesis of rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res 2008; 300: 125-131.
101. Koczulla R, von Degenfeld G, Kupatt C, Krötz F, Zahler S, Gloe T, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003; 111: 1665-1672.
102. Gomaa AH, Yaar M, Eyada MM, Bhawan J. Lymphangiogenesis in non-phymatous rosacea. J Cutan Pathol 2007; 34: 748-753.
103. Smith JR, Lanier VB, Braziel RM, Falkenhagen KM, White C, Rosenbaum JT. Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol 2007; 91: 226-229.
104. Huggenberger R, Detmar M. The cutaneous vascular system in chronic skin inflammation. J Investig Dermatol Symp Proc 2011; 15: 24-32.
105. Kim H, Kataru RP, Koh GY. Inflammation-associated lymphangiogenesis: a double-edged sword? J Clin Invest 2014; 124: 936-942.
106. Pereira ER, Liao N, Neale GA, Hendershot LM. Transcriptional and post-transcriptional regulation of proangiogenic factors by the unfolded protein response. PLoS One 2010; 5: e12521.
107. Sun P, Li X, Chen C, Chen Q, Ouyang Q, Liu F, et al. Activating transcription factor 4 modulates BDNF release from microglial cells. J Mol Neurosci 2014; 52: 225-230.
108. Kim JY, Kim YJ, Lim BJ, Sohn HJ, Shin D, Oh SH. Increased expression of cathelicidin by direct activation of protease-activated receptor 2: possible implications on the pathogenesis of rosacea. Yonsei Med J 2014; 55: 1648-1655.
109. Powell FC. Rosacea and the pilosebaceous follicle. Cutis 2004; 74: 9-12, 32-34.
110. Schmidt JB, Gebhart W, Raff M, Spona J. 13-cis-Retinoic acid in rosacea. Clinical and laboratory findings. Acta Derm Venereol 1984; 64: 15-21.
111. Zengin N, Tol H, Gündüz K, Balevi S, Endoğru H. Meibomian gland dysfunction and tear film abnormalities in rosacea. Cornea 1995; 14: 144-146.
112. House JS, Zhu S, Ranjan R, Linder K, Smart RC. C/ EBPalpha and C/EBPbeta are required for sebocyte differentiation and stratified squamous differentiation in adult mouse skin. PLoS One 2010; 5: e9837.
113. Tóth BI, Géczy T, Griger Z, Dózsa A, Seltmann H, Kovács L, et al. Transient receptor potential vanilloid-1 signaling as a regulator of human sebocyte biology. J Invest Dermatol 2009; 129: 329-339.
114. Lesnik RH, Kligman LH, Kligman AM. Agents that cause enlargement of sebaceous glands in hairless mice. I. Topical substances. Arch Dermatol Res 1992; 284: 100-105.
115. Lesnik RH, Kligman LH, Kligman AM. Agents that cause enlargement of sebaceous glands in hairless mice. II. Ultraviolet radiation. Arch Dermatol Res 1992; 284: 106-108.
116. Zouboulis CC, Baron JM, Böhm M, Kippenberger S, Kurzen H, Reichrath J, et al. Frontiers in sebaceous gland biology and pathology. Exp Dermatol 2008; 17: 542-551.
117. Schwalm S, Pfeilschifter J, Huwiler A. Sphingosine- 1-phosphate: a Janus-faced mediator of fibrotic diseases. Biochim Biophys Acta 2013; 1831: 239-250.
118. Kato A, Okura T, Hamada C, Miyoshi S, Katayama H, Higaki J, et al. Cell stress induces upregulation of osteopontin via the ERK pathway in type II alveolar epithelial cells. PLoS One 2014; 9: e100106.
119. Dalal S, Zha Q, Daniels CR, Steagall RJ, Joyner WL, Gadeau AP, et al. Osteopontin stimulates apoptosis in adult cardiac myocytes via the involvement of CD44 receptors, mitochondrial death pathway, and endoplasmic reticulum stress. Am J Physiol Heart Circ Physiol 2014; 306: H1182-H1191.
120. Sadick H, Goepel B, Bersch C, Goessler U, Hoermann K, Riedel F. Rhinophyma: diagnosis and treatment options for a disfiguring tumor of the nose. Ann Plast Surg 2008; 61: 114-120.
121. Ameri K, Harris AL. Activating transcription factor 4. Int J Biochem Cell Biol 2008; 40: 14-21.
122. Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell 2004; 117: 387-398.
123. Chiang CK, Hsu SP, Wu CT, Huang JW, Cheng HT, Chang YW, et al. Endoplasmic reticulum stress implicated in the development of renal fibrosis. Mol Med 2011; 17: 1295-1305.
124. Overley-Adamson B, Artlett CM, Stephens C, Sassi-Gaha S, Weis RD, Thacker JD. Targeting the unfolded protein response, XBP1, and the NLRP3 inflammasome in fibrosis and cancer. Cancer Biol Ther 2014; 15: 452-462.
125. Li X, Wang Y, Wang H, Huang C, Huang Y, Li J. Endoplasmic reticulum stress is the crossroads of autophagy, inflammation, and apoptosis signaling pathways and participates in liver fibrosis. Inflamm Res 2015; 64: 1-7.
126. Corallo C, Volpi N, Franci D, Montella A, Biagioli M, Mariotti G, et al. Is osteopontin involved in cutaneous fibroblast activation? Its hypothetical role in scleroderma pathogenesis. Int J Immunopathol Pharmacol 2014; 27: 97-102.
127. Wu M, Schneider DJ, Mayes MD, Wu M, Schneider DJ, Mayes MD, et al. Osteopontin in systemic sclerosis and its role in dermal fibrosis. J Invest Dermatol 2012; 132: 1605-1614.
128. Chang PL, Harkins L, Hsieh YH, Hicks P, Sappayatosok K, Yodsanga S, et al. Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem 2008; 56: 57-66.
129. Payne WG, Ko F, Anspaugh S, Wheeler CK, Wright TE, Robson MC. Down-regulating causes of fibrosis with tamoxifen: a possible cellular/molecular approach to treat rhinophyma. Ann Plast Surg 2006; 56: 301-305.
130. Carlson I, Tognazzi K, Manseau EJ, Dvorak HF, Brown LF. Osteopontin is strongly expressed by histiocytes in granulomas of diverse etiology. Lab Invest 1997; 77: 103-108.
131. Buback F, Renkl AC, Schulz G, Weiss JM. Osteopontin and the skin: multiple emerging roles in cutaneous biology and pathology. Exp Dermatol 2009; 18: 750-759.
132. Khajoee V, Saito M, Takada H, Nomura A, Kusuhara K, Yoshida SI, et al. Novel roles of osteopontin and CXC chemokine ligand 7 in the defence against mycobacterial infection. Clin Exp Immunol 2006; 143: 260-268.
133. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860-864.
134. Liu YN, Kang BB, Chen JH. Transcriptional regulation of human osteopontin promoter by C/EBPalpha and AML-1 in metastatic cancer cells. Oncogene 2004; 23: 278-288.
135. Staal A, van Wijnen AJ, Birkenhäger JC, Pols HA, Prahl J, DeLuca H, et al. Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences in the vitamin Dresponsive elements of the osteocalcin and osteopontin genes. Mol Endocrinol 1996; 10: 1444-1456.
136. Gollnick H, Blume-Peytavi U, Szabó EL, Meyer KG, Hauptmann P, Popp G, et al. Systemic isotretinoin in the treatment of rosacea- doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges 2010; 8: 505-515.
137. Del Rosso J Q, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis 2014; 93: 8-28.
138. Tsukada M, Schröder M, Roos TC, Chandraratna RA, Reichert U, Merk HF, et al. 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol 2000; 115: 321-327.
139. Liu PT, Krutzik SR, Kim J, Modlin RL. Cutting edge: alltrans retinoic acid down-regulates TLR2 expression and function. J Immunol 2005; 174: 2467-2470.
140. Dispenza MC, Wolpert EB, Gilliland KL, Dai JP, Cong Z, Nelson AM, et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012; 132: 2198-2205.
141. Borovaya A, Dombrowski Y, Zwicker S, Olisova O, Ruzicka T, Wolf R, et al. Isotretinoin therapy changes the expression of antimicrobial peptides in acne vulgaris. Arch Dermatol Res 2014; 306: 689-700.
142. Leyden JJ, James WD. Staphylococcus aureus infection as a complication of isotretinoin therapy. Arch Dermatol 1987; 123: 606-608.
143. Alikhan A, Kurek L, Feldman SR. The role of tetracyclines in rosacea. Am J Clin Dermatol 2010; 11: 79-87.
144. Sobolewska B, Doycheva D, Deuter C, Pfeffer I, Schaller M, Zierhut M. Treatment of ocular rosacea with once-daily low-dose doxycycline. Cornea 2014; 33: 257-260.
145. Henry C J, Huang Y, Wynne A, Hanke M, Himler J, Bailey MT, et al. Minocycline attenuates lipopolysaccaride (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation 2008; 5: 15.
146. Bastos LF, Godin AM, Zhang Y, Jarussophon S, Ferreira BC, Machado RR, et al. A minocycline derivative reduces nerve injury-induced allodynia, LPS-induced prostaglandin E2 microglial production and signaling via toll-like receptors 2 and 4. Neurosci Lett 2013; 543: 157-162.
147. Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikreinrelated peptidases and activation of cathelicidin. J Invest Dermatol 2012; 132: 1435-1442.
148. Korting HC, Schöllmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol 2009; 22: 287-294.
149. Görlach A, Klappa P, Kietzmann T. The endoplasmic reticulum: folding, calcium homeostasis, signaling, and redox control. Antioxid Redox Signal 2006; 8: 1391-1418.
150. Santos CX, Tanaka LY, Wosniak J, Laurindo FR. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal 2009; 11: 2409-2427.
151. Wolf JE Jr, Del Rosso JQ. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis 2007; 79: 73-80.
152. Narayanan S, Hünerbein A, Getie M, Jäckel A, Neubert RH. Scavenging properties of metronidazole on free oxygen radicals in a skin lipid model system. J Pharm Pharmacol 2007; 59: 1125-1130.
153. Tan X, Furio L, Reboud-Ravaux M, Villoutreix BO, Hovnanian A, El Amri C. 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin dieseases. Bioorg Med Chem Lett 2013; 23: 4547-4551.
154. Tan X, Bertonati C, Qin L, Furio L, El Amri C, Hovnanian A, et al. Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins. Eur J Med Chem 2013; 70: 661-668.
155. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75 % cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol 1999; 40: 961-965.
156. Liu RH, Smith MK, Basta SA, Farmer ER. Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials. Arch Dermatol 2006; 142: 1047-1052.
157. Coda AB, Hata T, Miller J, Audish D, Kotol P, Two A, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol 2013; 69: 570-577.
158. Jones DA. Rosacea, reactive oxygen species, and azelaic acid. J Clin Aesthet Dermatol 2009; 2: 26-30.
159. Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth- Jones J, Peirone MH, et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigatorblinded trial. Br J Dermatol 2015; 172: 1103-1110.
160. Ci X, Li H, Yu Q, Zhang X, Yu L, Chen N, et al. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. Fundam Clin Pharmacol 2009; 23: 449-455.
161. Zhang X, Song Y, Xiong H, Ci X, Li H, Yu L, et al. Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages. Int Immunopharmacol 2009; 9: 354-359.
162. Agliardi C, Guerini FR, Saresella M, Caputo D, Leone MA, Zanzottera M, et al. Vitamin D receptor (VDR) gene SNPs influence VDR expression and modulate protection from multiple sclerosis in HLA-DRB1*15-positive individuals. Brain Behav Immun 2011; 25: 1460-1467.
163. Hebbring SJ, Schrodi SJ, Ye Z, Zhou Z, Page D, Brilliant MH. A PheWAS approach in studying HLA-DRB1*1501. Genes Immun 2013; 14: 187-191.
164. Hebbring SJ. The challenges, advantages and future of phenome-wide association studies. Immunology 2014; 141: 157-165.
165. Roussel BD, Kruppa AJ, Miranda E, Crowther DC, Lomas DA, Marciniak SJ. Endoplasmic reticulum dysfunction in neurological disease. Lancet Neurol 2013; 12: 105-118.
166. McMahon JM, McQuaid S, Reynolds R, FitzGerald UF. Increased expression of ER stress- and hypoxia-associated molecules in grey matter lesions in multiple sclerosis. Mult Scler 2012; 18: 1437-1447.
167. Cunnea P, Mháille AN, McQuaid S, Farrell M, McMahon J, FitzGerald U. Expression profiles of endoplasmic reticulum stress-related molecules in demyelinating lesions and multiple sclerosis. Mult Scler 2011; 17: 808-818.
168. Wiersma VR, Michalak M, Abdullah TM, Bremer E, Eggleton P. Mechanisms of translocation of ER chaperones to the cell surface and immunomodulatory roles in cancer and autoimmunity. Front Oncol 2015; 5: 7.
169. Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 2013; 328: 9-18.
170. Yamout B, Zeineddine MM, Khoury SJ. Efficacy of lower fingolimod doses in the treatment of MS. Mult Scler Relat Disord. 2014; 3: 758.
171. Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, et al. Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial. Mult Scler Relat Disord 2014; 3: 752.
172. Prager B, Spampinato SF, Ransohoff RM. Sphingosine 1-phosphate signaling at the blood-brain barrier. Trends Mol Med 2015; 21: 354-363.
173. Brinnel H, Friedel J, Caputa M, Cabanac M, Grosshans E. Rosacea: disturbed defense against brain overheating. Arch Dermatol Res 1989; 281: 66-72.
174. Chang AL, Raber I, Xu J, Li R, Spitale R, Chen J, et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol 2015; 135: 1548-1555.
175. Kaser A, Martínez-Naves E, Blumberg RS. Endoplasmic reticulum stress: implications for inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 2010; 26: 318-326.
176. Hegde NR, Johnson DC. Human cytomegalovirus US2 causes similar effects on both major histocompatibility complex class I and II proteins in epithelial and glial cells. J Virol 2003; 77: 9287-9294.
177. Maingat F, Halloran B, Acharjee S, van Marle G, Church D, Gill MJ, et al. Inflammation and epithelial cell injury in AIDS enteropathy: involvement of endoplasmic reticulum stress. FASEB J 2011; 25: 2211-2220.
178. Zhu XM, Yao FH, Yao YM, Dong N, Yu Y, Sheng ZY. Endoplasmic reticulum stress and its regulator XBP-1 contributes to dendritic cell maturation and activation induced by high mobility group box-1 protein. Int J Biochem Cell Biol 2012; 44: 1097-1105.
179. Darlenski R, Kazandjieva J, Tsankov N, Fluhr JW. Acute irritant threshold correlates with barrier function, skin hydration and contact hypersensitivity in atopic dermatitis and rosacea. Exp Dermatol 2013; 22: 752-753.
180. Celli A, Mackenzie DS, Crumrine DS, Tu CL, Hupe M, Bikle DD, et al. ER Ca2+ depletion activates XBP1 and controls terminal differentiation in keratinocytes and epidermis. Br J Dermatol 2011; 164: 16-25.
181. Sakuntabhai A, Ruiz-Perez V, Carter S, Jacobsen N, Burge S, Monk S, et al. Mutations of ATP2A2, encoding a Ca2+ pump, cause Darrier disease. Nat Genet 1999; 21: 271-277.
182. Savignac M, Edir A, Simon M, Hovnanian A. Darier disease: a disease model of impaired calcium homeostasis in the skin. Biochim Biophys Acta 2011; 1813: 1111-1117.
183. Liang YH, Zhang QG, Liu QX. Two novel missense mutations of ATP2A2 in two Chinese patients with sporadic Darier disease. Clin Exp Dermatol 2015; 40: 201-203.
184. Savignac M, Simon M, Edir A, Guibbal L, Hovnanian A. SERCA2 Dysfunction in Darier disease causes endoplasmic reticulum stress and impaired cell-to-cell adhesion strength: rescue by Miglustat. J Invest Dermatol 2014; 134: 1961-1970.
185. Mauro T. Endoplasmic reticulum calcium, stress, and cellto- cell adhesion. J Invest Dermatol 2014; 134: 1800-1801.
186. Sheridan AT, Hollowood K, Sakuntabhai A, Dean D, Hovnanian A, Burge S, et al. Expression of sarco/endo-plasmic reticulum Ca2+-ATPase type 2 isoforms (SERCA2) in normal human skin and mucosa, and Darier's disease skin. Br J Dermatol 2002; 147: 670-674.
187. Puzianowska-Kuznicka M, Kuznicki J. The ER and ageing II: calcium homeostasis. Ageing Res Rev 2009; 8: 160-172.
188. Kihara Y, Mizuno H, Chun J. Lysophospholipid receptors in drug discovery. Exp Cell Res 2015; 333: 171-177.
189. Proia RL, Hla T. Emerging biology of sphingosine- 1-phosphate: its role in pathogenesis and therapy. J Clin Invest 2015; 125: 1379-1387.
190. Schümann J, Grevot A, Ledieu D, Wolf A, Schubart A, Piaia A, et al. Reduced activity of sphingosine-1-phosphate lyase induces podocyte-related glomerular proteinuria, skin irritation, and platelet activation. Toxicol Pathol 2015; 43: 694-703.
191. Claas RF, ter Braak M, Hegen B, Hardel V, Angioni C, Schmidt H, et al. Enhanced Ca2+ storage in sphingosine- 1-phosphate lyase-deficient fibroblasts. Cell Signal 2010; 22: 476-483.
192. Itagaki K, Yun JK, Hengst JA, Yatani A, Hauser CJ, Spolarics Z, et al. Sphingosine 1-phosphate has dual functions in the regulation of endothelial cell permeability and Ca2+ metabolism. J Pharmacol Exp Ther 2007; 323: 186-191.
193. Conlledo R, Guglielmetti A, Sobarzo M, Woolvett F, Bravo F, González S, et al. Lewandowsky's rosaceiform eruption: a form of cutaneous tuberculosis confirmed by PCR in two patients. Dermatol Ther (Heidelb) 2015; 5: 67-76.
194. Gøtzsche PC. Niels Finsen's treatment for lupus vulgaris. J R Med 2011; 104: 41-42.
195. Seimon TA, Kim MJ, Blumenthal A, Ehrt S, Wainwright H, Bekker LG, et al. Induction of ER stress in macrophages of tuberculosis granulomas. PLoS One. 2010; 5: e12772.
196. Saquib NM, Jamwal S, Midha MK, Verma HN, Manivel V. Quantitative proteomics and lipidomics analysis of endoplasmic reticulum of macrophage infected with Mycobacterium tuberculosis. Int J Proteomics. 2015; 2015: 270438.
197. Frew L, Makieva S, McKinlay AT, McHugh BJ, Doust A, Norman JE, et al. Human cathelicidin production by the cervix. PLoS One 2014; 9: e103434.
198. Mandic Havelka A, Yektaei-Karin E, Hultenby K, Sørensen OE, Lundahl J, Berggren V, et al. Maternal plasma level of antimicrobial peptide LL37 is a major determinant factor of neonatal plasma LL37 level. Acta Paediatr 2010; 99: 836-841.
199. Kai-Larsen Y, Bergsson G, Gudmundsson GH, Printz G, Jörnvall H, Marchini G, et al. Antimicrobial components of the neonatal gut affected upon colonization. Pediatr Res 2007; 61: 530-536.